Novo Nordisk's High-Dose Wegovy Shows 27.7% Weight Loss in Early Responders — But the Fine Print Matters

But pump the brakes before calling it a Zepbound killer.

First, that 27.7% figure applies to roughly 1 in 4 patients on the highest dose. The overall average for everyone on that dose was about 21% — still competitive, but less dramatic. The previous 2.4mg Wegovy dose produced 17% weight loss on average at the same timeframe, according to CNBC's reporting on the Novo data.

Second — and this is what most coverage is glossing over — there is no comparable "early responder" dataset for Zepbound. Novo is essentially comparing its best-case patients against Lilly's overall averages. That's not a clean comparison. It's a marketing frame dressed up as science.

Why Novo Is Doing This Now

Context matters. Novo launched the 7.2mg dose in the U.S. just one month ago. Eli Lilly's Zepbound has been eating Wegovy's lunch on efficacy — Zepbound's late-stage trials showed more than 20% average weight loss, which is why it became the preferred drug among prescribers.

Novo needs a narrative reset. The new high-dose data gives them one — selectively. Three of the largest pharmacy benefit managers in the U.S. have already added the 7.2mg dose to their standard formularies as a Wegovy extension, according to CNBC. Novo said on its earnings call last week it's already seeing patients ramp up to the new dose.

The company is fighting for market share. This data release — timed one month post-launch — is as much a commercial move as a scientific one. The drug's efficacy is real. It's just the reality of how pharma operates.

A New Challenger Nobody's Talking About

While the Novo-Lilly rivalry dominates headlines, a smaller biotech is quietly making a serious play.

MBX Biosciences — up more than 230% over the past year — is developing a GLP-1 and GIPR receptor drug still in Phase 1 trials. UBS analyst Michael Yee issued a buy rating Monday with a $60 price target, implying nearly 50% upside from Friday's close, according to CNBC.

Yee's note said MBX Biosciences' drug showed "slightly more effective" four-week weight loss results than tirzepatide — that's Lilly's active ingredient in Zepbound — and, critically, significantly better tolerability. Nausea and GI side effects are the primary reason patients quit GLP-1 drugs. A drug that works as well and feels better to take is a legitimate differentiator.

Ten of 11 analysts covering MBX rate it a buy or strong buy. This is Phase 1 data — early, small-sample, not definitive. But the direction is notable.

The $190 Billion Elephant in the Room

Morgan Stanley's Terence Flynn, who leads U.S. pharma and biotech coverage, put out a forecast in April 2026 projecting the global GLP-1 market could hit $190 billion by 2035 — up from $79 billion in combined type-2 diabetes and obesity sales in 2025. That's more than double in a decade.

The two key drivers, per Morgan Stanley: oral GLP-1 formulations hitting the market and expanded Medicare coverage in the U.S. Currently about 6% of obese or diabetic Americans use GLP-1 therapies. Morgan Stanley's base case gets that to nearly 30% by 2035.

Flynn flagged one real risk: inflation. A "large percentage" of GLP-1 sales are out-of-pocket. If household budgets tighten, expensive weight-loss drugs are a discretionary cut. That risk is getting underreported.

What Mainstream Coverage Is Missing

Most outlets are running the Novo data at face value — "Wegovy beats Zepbound!" — without drilling into the early-responder caveat. That framing is sloppy at best, misleading at worst.

The harder question remains unanswered: what does Zepbound's early-responder data look like? Until Lilly publishes comparable subgroup analysis, the 27.7% figure is scientifically interesting but competitively inconclusive.

Also underreported: the pipeline beyond Novo and Lilly. Ozmosi's market analysis identified 39 new GLP-1 drugs in development from 34 companies as of late 2025, with many emerging players based in China. If Chinese-manufactured GLP-1 generics flood international markets — particularly Brazil and India — the pricing dynamics for Novo and Lilly get complicated fast.

What This Means For You

If you're a patient: the new high-dose Wegovy is real, the 28% number is real for some people — but you won't know if you're one of them until you're six months in. Manage expectations accordingly.

If you're a taxpayer: Medicare is about to start covering more of this at scale. The $190 billion market projection isn't just pharma profit — it's a coming collision between genuine public health value and serious fiscal exposure. Nobody in Washington is having that conversation seriously yet.

The drugs work. The market is enormous. The political and fiscal reckoning is coming.